Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al.
Affiliation
Warwick Medical School, University of Warwick, Coventry, UKIssue Date
2016-10
Metadata
Show full item recordCitation
Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al. 2016, 28 (10):666-7 Clin OncolJournal
Clinical OncologyDOI
10.1016/j.clon.2016.07.004PubMed ID
27477123Type
ArticleLanguage
enISSN
1433-2981ae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2016.07.004
Scopus Count
Collections
Related articles
- High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice.
- Authors: Tanguay JS, Catlow C, Smith C, Barber J, Staffurth J, Kumar S, Palaniappan N, Button M, Mason MD
- Issue date: 2016 Sep
- Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
- Authors: Rulach RJ, McKay S, Neilson S, White L, Wallace J, Carruthers R, Lamb C, Cascales A, Marashi H, Glen H, Venugopal B, Sadoyze A, Sidek N, Russell JM, Alhasso A, Dodds D, Laskey J, Jones RJ, MacLeod N
- Issue date: 2018 Feb
- Should docetaxel be administered earlier in prostate cancer therapy?
- Authors: Graff JN, Beer TM
- Issue date: 2015